



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Zichria ZAKAY-RONES et al.

Confirmation No. 1732

Application No.: 10/800,256

Group Art Unit: 1614

Filing Date: March 11, 2004

Examiner:

For: COMPOSITIONS AND METHODS  
FOR TREATMENT OF CANCER

Atty. Docket No.: 85189-5900

**REQUEST FOR CORRECTION OF FILING RECEIPT**

Office of Initial Patent Examination  
Customer Service Center  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

A filing receipt for the above-identified application has been received and the following corrections are respectfully requested:

Please correct the filing date of the foreign priority data to read as follows:

**--ISRAEL IL 145397 filed September 12, 2001--**

A copy of the International Application publication WO 03/022202 indicated the priority data is enclosed for verification. Also copies of the incorrect filing receipt with changes noted thereon along with a copy of the executed inventors' declaration are enclosed herewith in support of this change. No fee is believed to be due for this submission. Please charge any required fees to WINSTON & STRAWN LLP Deposit Account No. 50-1814.

Respectfully submitted,

Date: \_\_\_\_\_

*10/8/04*

*Allan A. Fanucci*

Allan A. Fanucci (Reg. No. 30,256)

**WINSTON & STRAWN LLP**  
**CUSTOMER NO. 28765**  
(212) 294-3311

Enclosures



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/800,256	03/11/2004	1614	615	85189-5900	13	36	5

28765  
 WINSTON & STRAWN  
 PATENT DEPARTMENT  
 1400 L STREET, N.W.  
 WASHINGTON, DC 20005-3502

**RECEIVED****AUG 16 2004**

WINSTON & STRAWN LLP  
 DOCKETING DEPT. (D.C.)

CONFIRMATION NO. 1732

## FILING RECEIPT



\*OC000000013515439\*

Date Mailed: 08/12/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Zichria Zakay-Rones, Jerusalem, ISRAEL;  
 Amos Panet, Mevaseret Zion, ISRAEL;  
 Charles Irving, Caeseria, ISRAEL;

## Domestic Priority data as claimed by applicant

This application is a CON of PCT/IL02/00765 09/12/2002

## Foreign Applications

ISRAEL IL145397 09/13/2001

*12 - change date  
 September 12, 2001*

If Required, Foreign Filing License Granted: 05/30/2004

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

**\*\* SMALL ENTITY \*\***

Title

## Compositions and methods for treatment of cancer

## Preliminary Class

514

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
20 March 2003 (20.03.2003)

PCT

(10) International Publication Number  
**WO 03/022202 A2**

- (51) International Patent Classification<sup>7</sup>: **A61K**
- (21) International Application Number: **PCT/IL02/00765**
- (22) International Filing Date:  
12 September 2002 (12.09.2002)
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:  
145397 12 September 2001 (12.09.2001) **IL**
- (71) Applicants (*for all designated States except US*): **YIS-SUM RESEARCH DEVELOPMENT COMPANY** [IL/IL]; The Hebrew University of Jerusalem, P.O. Box 39135, 91390 Jerusalem (IL). **OVCURE INC.** [US/US]; 666 Old Country Road, 302 Garden City, New York, NY 11552 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **ZAKAY-RONES, Zichria** [IL/IL]; Palmach Street 52A, 92583 Jerusalem (IL). **PANET, Amos** [IL/IL]; Agat Street 6, Apt. 9, 90805 Mevaseret Zion (IL). **IRVING, Charles** [US/IL]; Hashezif Street 9, 38900 Caeseria (IL).
- (74) Agent: **WEBB, Cynthia**; Webb & Associates, P.O. Box 2189, 76121 Rehovot (IL).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— *without international search report and to be republished upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER

(57) Abstract: The present invention discloses lentogenic viral strains useful in the treatment of cancer. A preferred viral strain of Newcastle disease Virus (NDV) is specifically characterized in terms of biological activities. The present invention further discloses treatment of cancer by application of a clonal NDV strain to tumors. According to an alternative preferred embodiment the use of at least one isolated viral protein or subunit or analog thereof, or an isolated polynucleotide encoding same, is used in the treatment of cancer.



**WO 03/022202 A2**